Compare · MRK vs PHVS
MRK vs PHVS
Side-by-side comparison of Merck & Company Inc. (MRK) and Pharvaris N.V. (PHVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and PHVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $295.19B, about 134.1x PHVS ($2.20B).
- Over the past year, MRK is up 50.7% and PHVS is up 75.6% - PHVS leads by 24.9 points.
- MRK has been more active in the news (27 items in the past 4 weeks vs 13 for PHVS).
- MRK has more recent analyst coverage (25 ratings vs 13 for PHVS).
- Company
- Merck & Company Inc.
- Pharvaris N.V.
- Price
- $119.49-1.15%
- $31.68+1.64%
- Market cap
- $295.19B
- $2.20B
- 1M return
- +6.40%
- +6.87%
- 1Y return
- +50.70%
- +75.58%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 27
- 13
- Recent ratings
- 25
- 13
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Pharvaris N.V.
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks; and PHVS719, a prophylactic extended-release tablet for HAE patients. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is headquartered in Leiden, the Netherlands.
Latest MRK
- Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
- Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity
- SEC Form 4 filed by Director Warden Kathy J
- SEC Form 4 filed by Director Karsanbhai Surendralal Lanca
- SEC Form 4 filed by Director Coe Mary Ellen
- SEC Form 4 filed by Director Thulin Inge G
- SEC Form 4 filed by Director Seidman Christine E
- SEC Form 4 filed by Director Russo Patricia F
- SEC Form 4 filed by Director Rothman Paul
- SEC Form 4 filed by Director Mayo Stephen
Latest PHVS
- Principal Accounting Officer Nijdam Anna sold $82,425 worth of shares (2,670 units at $30.87), decreasing direct ownership by 5% to 46,275 units (SEC Form 4)
- Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026
- Director Monges Viviane sold $292,853 worth of shares (9,667 units at $30.29), decreasing direct ownership by 64% to 5,500 units (SEC Form 4) to satisfy tax liability
- Principal Accounting Officer Nijdam Anna exercised 7,330 shares at a strike of $20.00 and sold $225,055 worth of shares (7,330 units at $30.70) (SEC Form 4) to satisfy withholding obligation
- CFO / CLO Nassif David W. sold $303,076 worth of shares (10,000 units at $30.31), decreasing direct ownership by 8% to 120,300 units (SEC Form 4) to satisfy withholding obligation
- Director Bjork Elisabeth exercised 10,000 shares at a strike of $8.05 and sold $293,166 worth of shares (10,000 units at $29.32) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: SEC Form 4 filed by Chief Executive Officer Modig Berndt
- SEC Form 144 filed by Pharvaris N.V.
- Chief Executive Officer Modig Berndt sold $66,977 worth of shares (2,292 units at $29.22) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 137,500 units (SEC Form 4)
- SEC Form 144 filed by Pharvaris N.V.